Expertise in
34
conditions

Dr. Pierre Giglio

Neurology
Ohio State University Hospital-Pavilion
300 W 10th Ave, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
34
conditions
Ohio State University Hospital-Pavilion
300 W 10th Ave, 
Columbus, OH 

Overview

Pierre Giglio is a Neurologist practicing medicine in Columbus, Ohio.

Dr. Giglio is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

He is actively involved in clinical research, co-authoring 72 peer reviewed articles and participating in 10 clinical trials. Dr. Giglio is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in OH

Hospital Affiliations

Ohio State University State Health System
Blanchard Valley Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Ohio State University Hospital-Pavilion
300 W 10th Ave, Columbus, OH 43210

Additional Areas of Focus

Dr. Giglio has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Biological
Study Drugs: Bevacizumab, Cediranib, Cediranib Maleate, Olaparib
Study Phase: Phase 2
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
Enrollment Status: Completed
Publish Date: June 08, 2025
Intervention Type: Drug, Radiation
Study Drugs: BMX-001, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma
Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma
Enrollment Status: Suspended
Publish Date: February 22, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
The Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma
The Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma
Enrollment Status: Withdrawn
Publish Date: January 31, 2018
Intervention Type: Procedure, Drug, Other
Study Phase: Not Applicable
View 8 Less Clinical Trials

72 Total Publications

Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.
Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.
Journal: Journal of neuro-oncology
Published: June 10, 2026
Similar Doctors
Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Nationwide Children's Hospital

700 Childrens Dr, 
Columbus, OH 
 (3.5 miles away)
614-722-2203
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Dr. Jerry Mendell, MD is a Neurology Specialist in Columbus, OH and has over 56 years of experience in the medical field. He graduated from University of Texas Southwestern Medical School in 1966. Dr. Mendell is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, and Spinal Muscular Atrophy (SMA). Dr. Mendell is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral required
Before you request

Nationwide Children's Hospital

700 Childrens Dr, 
Columbus, OH 
 (3.5 miles away)
614-722-4625
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anup Patel is a Neurologist practicing medicine in Columbus, Ohio. Dr. Patel is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Epilepsy, Lennox-Gastaut Syndrome (LGS), West Syndrome, and Seizures. Dr. Patel is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Ohio State Dodd Rehabilitation Hospital

480 Medical Center Dr, 
Columbus, OH 
 (0.3 miles away)
614-293-4969
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Aristide Merola is a Neurologist practicing medicine in Columbus, Ohio. Dr. Merola is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Movement Disorders, Parkinson's Disease, Familial Dysautonomia, Low Blood Pressure, and Deep Brain Stimulation. Dr. Merola is currently accepting new patients.

Frequently Asked Questions about Dr. Pierre Giglio

How do I make an appointment with Dr. Pierre Giglio?

You can book an appointment with Dr. Pierre Giglio by calling their office at 614-366-7744. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Pierre Giglio a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Pierre Giglio is classified as an Elite expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Pierre Giglio specialize in?

While Dr. Pierre Giglio is a Neurology, they have specific expertise in Glioblastoma, Astrocytoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Pierre Giglio participate in research or clinical trials?

Yes. Dr. Pierre Giglio has published 72 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. Pierre Giglio's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Pierre Giglio accept my insurance?

Dr. Pierre Giglio accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-366-7744 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Giglio's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 17 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile